AIM ImmunoTech is trading 5.26% down at $0.17, with no clear company-specific catalyst for the September 29 move.
- The company’s press-release page lists September 22 as its latest release; no new September 29 announcement surfaced in available coverage.
- Major indexes declined modestly, but none fell more than 0.5%, so the available evidence does not establish a broad-market explanation.
- Volume and intraday trading activity were not provided.